These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28652542)

  • 21. Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling.
    Verheijen M; Schrooders Y; Gmuender H; Nudischer R; Clayton O; Hynes J; Niederer S; Cordes H; Kuepfer L; Kleinjans J; Caiment F
    Toxicol Lett; 2018 Sep; 294():184-192. PubMed ID: 29803840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological senolysis reduces doxorubicin-induced cardiotoxicity and improves cardiac function in mice.
    Lérida-Viso A; Estepa-Fernández A; Morellá-Aucejo Á; Lozano-Torres B; Alfonso M; Blandez JF; Bisbal V; Sepúlveda P; García-Fernández A; Orzáez M; Martínez-Máñez R
    Pharmacol Res; 2022 Sep; 183():106356. PubMed ID: 35843569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Foxo3a inhibits mitochondrial fission and protects against doxorubicin-induced cardiotoxicity by suppressing MIEF2.
    Zhou L; Li R; Liu C; Sun T; Htet Aung LH; Chen C; Gao J; Zhao Y; Wang K
    Free Radic Biol Med; 2017 Mar; 104():360-370. PubMed ID: 28137654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sesamin ameliorates doxorubicin-induced cardiotoxicity: involvement of Sirt1 and Mn-SOD pathway.
    Su S; Li Q; Liu Y; Xiong C; Li J; Zhang R; Niu Y; Zhao L; Wang Y; Guo H
    Toxicol Lett; 2014 Jan; 224(2):257-63. PubMed ID: 24211423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-21 Protected Cardiomyocytes against Doxorubicin-Induced Apoptosis by Targeting BTG2.
    Tong Z; Jiang B; Wu Y; Liu Y; Li Y; Gao M; Jiang Y; Lv Q; Xiao X
    Int J Mol Sci; 2015 Jun; 16(7):14511-25. PubMed ID: 26132560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity.
    Fan GC; Zhou X; Wang X; Song G; Qian J; Nicolaou P; Chen G; Ren X; Kranias EG
    Circ Res; 2008 Nov; 103(11):1270-9. PubMed ID: 18948619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
    Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
    Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Grape seed proanthocyanidins ameliorate Doxorubicin-induced cardiotoxicity.
    Li J; Liu H; Ramachandran S; Waypa GB; Yin JJ; Li CQ; Han M; Huang HH; Sillard WW; Vanden Hoek TL; Shao ZH
    Am J Chin Med; 2010; 38(3):569-84. PubMed ID: 20503473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paradoxically, iron overload does not potentiate doxorubicin-induced cardiotoxicity in vitro in cardiomyocytes and in vivo in mice.
    Guenancia C; Li N; Hachet O; Rigal E; Cottin Y; Dutartre P; Rochette L; Vergely C
    Toxicol Appl Pharmacol; 2015 Apr; 284(2):152-62. PubMed ID: 25711856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amelioration of doxorubicin‑induced cardiotoxicity by resveratrol.
    Al-Harthi SE; Alarabi OM; Ramadan WS; Alaama MN; Al-Kreathy HM; Damanhouri ZA; Khan LM; Osman AM
    Mol Med Rep; 2014 Sep; 10(3):1455-60. PubMed ID: 25059399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
    Ammar el-SM; Said SA; Suddek GM; El-Damarawy SL
    Can J Physiol Pharmacol; 2011 Apr; 89(4):269-76. PubMed ID: 21526973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extract of
    Shi Y; Wu Y; Shen M; Yang J; Qin Y; Liu S; Sun C
    Integr Cancer Ther; 2023; 22():15347354231164621. PubMed ID: 37029546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity.
    Gu J; Hu W; Song ZP; Chen YG; Zhang DD; Wang CQ
    Int Immunopharmacol; 2016 Mar; 32():1-7. PubMed ID: 26774212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
    Jo A; Choi TG; Jo YH; Jyothi KR; Nguyen MN; Kim JH; Lim S; Shahid M; Akter S; Lee S; Lee KH; Kim W; Cho H; Lee J; Shokat KM; Yoon KS; Kang I; Ha J; Kim SS
    Antioxid Redox Signal; 2017 Jan; 26(2):70-83. PubMed ID: 27357096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.
    Xiao J; Sun GB; Sun B; Wu Y; He L; Wang X; Chen RC; Cao L; Ren XY; Sun XB
    Toxicology; 2012 Feb; 292(1):53-62. PubMed ID: 22155320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardioprotective Potentials of Plant-Derived Small Molecules against Doxorubicin Associated Cardiotoxicity.
    Ojha S; Al Taee H; Goyal S; Mahajan UB; Patil CR; Arya DS; Rajesh M
    Oxid Med Cell Longev; 2016; 2016():5724973. PubMed ID: 27313831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential targets for intervention against doxorubicin-induced cardiotoxicity based on genetic studies: a systematic review of the literature.
    Chen Y; Huang T; Shi W; Fang J; Deng H; Cui G
    J Mol Cell Cardiol; 2020 Jan; 138():88-98. PubMed ID: 31751567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Adrenomedullin on Doxorubicin-Induced Cardiac Damage in Mice.
    Yoshizawa T; Takizawa S; Shimada S; Tokudome T; Shindo T; Matsumoto K
    Biol Pharm Bull; 2016 May; 39(5):737-46. PubMed ID: 26902282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP1B1 inhibition attenuates doxorubicin-induced cardiotoxicity through a mid-chain HETEs-dependent mechanism.
    Maayah ZH; Althurwi HN; Abdelhamid G; Lesyk G; Jurasz P; El-Kadi AO
    Pharmacol Res; 2016 Mar; 105():28-43. PubMed ID: 26772815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.